Pentavalent vaccination in Kenya: coverage and geographical accessibility to health facilities using data from a community demographic and health surveillance system in Kilifi County.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
25 04 2022
Historique:
received: 29 10 2020
accepted: 11 01 2022
entrez: 26 4 2022
pubmed: 27 4 2022
medline: 28 4 2022
Statut: epublish

Résumé

There is substantial evidence that immunization is one of the most significant and cost-effective pillars of preventive and promotive health interventions. Effective childhood immunization coverage is thus essential in stemming persistent childhood illnesses. The third dose of pentavalent vaccine for children is an important indicator for assessing performance of the immunisation programme because it mirrors the completeness of a child's immunisation schedule. Spatial access to an immunizing health facility, especially in sub-Sahara African (SSA) countries, is a significant determinant of Pentavalent 3 vaccination coverage, as the vaccine is mainly administered during routine immunisation schedules at health facilities. Rural areas and densely populated informal settlements are most affected by poor access to healthcare services. We therefore sought to determine vaccination coverage of Pentavalent 3, estimate the travel time to health facilities offering immunisation services, and explore its effect on immunisation coverage in one of the predominantly rural counties on the coast of Kenya. We used longitudinal survey data from the health demographic surveillance system implemented in Kaloleni and Rabai Sub-counties in Kenya. To compute the geographical accessibility, we used coordinates of health facilities offering immunisation services, information on land cover, digital elevation models, and road networks of the study area. We then fitted a hierarchical Bayesian multivariable model to explore the effect of travel time on pentavalent vaccine coverage adjusting for confounding factors identified a priori. Overall coverage of pentavalent vaccine was at 77.3%. The median travel time to a health facility was 41 min (IQR = 18-65) and a total of 1266 (28.5%) children lived more than one-hour of travel-time to a health facility. Geographical access to health facilities significantly affected pentavalent vaccination coverage, with travel times of more than one hour being significantly associated with reduced odds of vaccination (AOR = 0.84 (95% CI 0.74 - 0.94). Increased travel time significantly affects immunization in this rural community. Improving road networks, establishing new health centres and/or stepping up health outreach activities that include vaccinations in hard-to-reach areas within the county could improve immunisation coverage. These data may be useful in guiding the local department of health on appropriate location of planned immunization centres.

Sections du résumé

BACKGROUND
There is substantial evidence that immunization is one of the most significant and cost-effective pillars of preventive and promotive health interventions. Effective childhood immunization coverage is thus essential in stemming persistent childhood illnesses. The third dose of pentavalent vaccine for children is an important indicator for assessing performance of the immunisation programme because it mirrors the completeness of a child's immunisation schedule. Spatial access to an immunizing health facility, especially in sub-Sahara African (SSA) countries, is a significant determinant of Pentavalent 3 vaccination coverage, as the vaccine is mainly administered during routine immunisation schedules at health facilities. Rural areas and densely populated informal settlements are most affected by poor access to healthcare services. We therefore sought to determine vaccination coverage of Pentavalent 3, estimate the travel time to health facilities offering immunisation services, and explore its effect on immunisation coverage in one of the predominantly rural counties on the coast of Kenya.
METHODS
We used longitudinal survey data from the health demographic surveillance system implemented in Kaloleni and Rabai Sub-counties in Kenya. To compute the geographical accessibility, we used coordinates of health facilities offering immunisation services, information on land cover, digital elevation models, and road networks of the study area. We then fitted a hierarchical Bayesian multivariable model to explore the effect of travel time on pentavalent vaccine coverage adjusting for confounding factors identified a priori.
RESULTS
Overall coverage of pentavalent vaccine was at 77.3%. The median travel time to a health facility was 41 min (IQR = 18-65) and a total of 1266 (28.5%) children lived more than one-hour of travel-time to a health facility. Geographical access to health facilities significantly affected pentavalent vaccination coverage, with travel times of more than one hour being significantly associated with reduced odds of vaccination (AOR = 0.84 (95% CI 0.74 - 0.94).
CONCLUSION
Increased travel time significantly affects immunization in this rural community. Improving road networks, establishing new health centres and/or stepping up health outreach activities that include vaccinations in hard-to-reach areas within the county could improve immunisation coverage. These data may be useful in guiding the local department of health on appropriate location of planned immunization centres.

Identifiants

pubmed: 35468754
doi: 10.1186/s12889-022-12570-w
pii: 10.1186/s12889-022-12570-w
pmc: PMC9040218
doi:

Substances chimiques

Vaccines, Combined 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

826

Informations de copyright

© 2022. The Author(s).

Références

Int J Health Geogr. 2004 Feb 26;3(1):3
pubmed: 14987337
Soc Sci Med. 2015 Apr;130:135-45
pubmed: 25697636
BMC Public Health. 2012 Jun 22;12:476
pubmed: 22726457
Sci Data. 2019 Jul 25;6(1):134
pubmed: 31346183
BMJ Glob Health. 2017 Oct 23;2(4):e000468
pubmed: 29104769
Lancet Glob Health. 2018 Mar;6(3):e342-e350
pubmed: 29396220
PLoS One. 2012;7(5):e37905
pubmed: 22662247
Vaccine. 2018 Mar 14;36(12):1583-1591
pubmed: 29454519
Vaccine. 2011 Oct 26;29(46):8215-21
pubmed: 21893149
Arch Dis Child. 2020 Jul;105(7):648-654
pubmed: 32169853
Trop Med Int Health. 2006 Feb;11(2):188-96
pubmed: 16451343
Health Syst Reform. 2016 Apr 2;2(2):112-118
pubmed: 31514640
Pan Afr Med J. 2017 Sep 13;28:21
pubmed: 29138657
Health Econ Rev. 2018 Apr 11;8(1):9
pubmed: 29644503
Asia Pac J Public Health. 2016 Mar;28(2):167-77
pubmed: 26809971
MMWR Morb Mortal Wkly Rep. 2015 Nov 13;64(44):1252-5
pubmed: 26562454
BMC Public Health. 2006 May 17;6:132
pubmed: 16707013
Geospat Health. 2017 May 11;12(1):510
pubmed: 28555479
BMJ Glob Health. 2018 Nov 28;3(6):e001136
pubmed: 30588346
BMC Health Serv Res. 2018 Apr 19;18(1):291
pubmed: 29673360
PLoS One. 2017 Feb 27;12(2):e0172728
pubmed: 28241032
Int J Equity Health. 2015 Feb 27;14:24
pubmed: 25889450
J Epidemiol Community Health. 2018 Aug;72(8):719-725
pubmed: 29581228
Public Health. 2015 Nov;129(11):1530-8
pubmed: 26278475
Int J Epidemiol. 2020 Jun 1;49(3):758-759e
pubmed: 31872230
Asia Pac J Public Health. 2019 Jan;31(1):51-60
pubmed: 30499306
BMJ Glob Health. 2019 Jul 1;4(Suppl 5):e001406
pubmed: 31321092
Vaccine. 2012 Dec 14;30(52):7588-93
pubmed: 23102973
Malar J. 2017 Sep 12;16(1):367
pubmed: 28899379
AIDS Behav. 2014 Jul;18(7):1199-223
pubmed: 24563115
Trop Med Int Health. 2011 Sep;16(9):1044-53
pubmed: 21707877
East Afr Med J. 2009 Jul;86(7):323-9
pubmed: 20499781
Am J Trop Med Hyg. 2014 Feb;90(2):234-41
pubmed: 24343886
Int Health. 2012 Dec;4(4):229-38
pubmed: 24029668

Auteurs

Morris Ogero (M)

Department of Population Health, Aga Khan University, Nairobi, Kenya. ogeromorris@gmail.com.
School of Mathematics, University of Nairobi, Nairobi, Kenya. ogeromorris@gmail.com.
Health Services Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya. ogeromorris@gmail.com.

James Orwa (J)

Department of Population Health, Aga Khan University, Nairobi, Kenya.

Rachael Odhiambo (R)

Department of Population Health, Aga Khan University, Nairobi, Kenya.
Institute for Human Development, Aga Khan University, Nairobi, Kenya.

Felix Agoi (F)

Department of Population Health, Aga Khan University, Nairobi, Kenya.

Adelaide Lusambili (A)

Department of Population Health, Aga Khan University, Nairobi, Kenya.

Jerim Obure (J)

Centre of Excellence for Women and Child Health, Aga Khan University, Nairobi, Kenya.

Marleen Temmerman (M)

Centre of Excellence for Women and Child Health, Aga Khan University, Nairobi, Kenya.
Department of Obstetrics and Gynaecology, Aga Khan University, Nairobi, Kenya.
International Centre for Reproductive Health, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.

Stanley Luchters (S)

Department of Population Health, Aga Khan University, Nairobi, Kenya.
International Centre for Reproductive Health, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Burnet Institute, Melbourne, Australia.

Anthony Ngugi (A)

Department of Population Health, Aga Khan University, Nairobi, Kenya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH